Bioseutica Research & Development teams are experts in extraction technologies, protein-purification, process engineering, and microbiological research.
We have a long track record in developing new products, proprietary production techniques, and innovative applications for the food, feed, animal health, and pharmaceutical industries. This is also reflected by the company's strong IP portfolio including trademarks and patents. Bioseutica and its affiliates hold more than 15 key patents in countries all over the world as well as more than 10 new patent applications which will further strengthen the company's long-term IP position. Our IP portfolio covers a broad range of applications, and manufacturing processes in the fields of omega-3 fatty acids, Natural Proteins, and pharmaceutical applications.
Bioseutica’s team of scientists, researchers, and R&D specialists are located in Taverne (Switzerland) and Abbotsford (Canada). Bioseutica's competitive edge is due to the R&D teams' dedication to a thorough understanding of our products, our processes, and modern developments in our various fields of research. We have a track record of pioneering and leading the way in developing new market applications such as the use of lysozyme as a natural ingredient in the production of wine and beer. We have active research collaborations with world-class academic institutions and private partners such as the universities of Gent, Liegè, Edinburgh, and Graz, Trinity College Dublin, Agriculture, and Agri-Food Canada. Oregon State University, Yale University, Universita di Udine, ITV France, AWRI (Australian Wine Research Institute), and the University of Wisconsin among others.
In the Natural Protein Division, the team is developing new applications for its pharmaceutical-grade lysozyme and other naturally occurring bioactive proteins. New applications are also being developed for the food protection and animal health industries. Finally, SPK-843, Bioseutica's new experimental drug for the treatment of severe, life-threatening fungal infections is currently in late-stage clinical trials.
Combating Antibiotic Resistance: A Critical Mission of Bioseutica®
Understanding Antibiotic Resistance
Antibiotic resistance occurs when bacteria evolve and become resistant to the antibiotics used to treat the infections they cause. This alarming phenomenon transforms previously manageable infections into untreatable health threats. According to the World Health Organization, antibiotic-resistant pathogens now account for over 700,000 deaths annually, a number projected to rise exponentially, posing a severe global health risk.
Current statistics indicate that over 300 million people worldwide suffer from a serious Fungal Infection, with around 25 million at high risk of life-threatening consequences or vision loss.
The Urgency of New Antibiotics Development
The escalating crisis of antibiotic resistance necessitates the urgent development of new, effective antibiotics. Traditional treatments are increasingly failing, and without innovative solutions, we face a future where routine surgeries and minor infections could carry life-threatening risks.
Tackling Systemic Fungal Infections
Fungal infections, often overlooked, are a critical part of the antibiotic resistance problem. Systemic fungal infections, particularly in immunocompromised individuals, present a significant treatment challenge due to the limited efficacy of current medications and the rise of resistant strains.
Fighting Fungal Infections in Cystic Fibrosis
Cystic fibrosis patients frequently encounter severe fungal infections, necessitating effective prophylaxis and treatment strategies. The complexity of these infections in such patients underlines the need for more specialized antifungal therapies.
Addressing Candida Auris and Aspergillosis
Candida auris and Aspergillosis, particularly their invasive forms, represent growing global health concerns due to their increasing resistance to existing treatments. Developing drugs that can effectively combat these infections is of paramount importance.
Combating Candidiasis and Cryptococcus Neoformans
Invasive candidiasis and Cryptococcus neoformans infections pose significant risks, especially in hospital settings. Effective treatment of these infections is hindered by the growing resistance to current antifungals.
Challenges in Cystic Fibrosis and HIV
Allergic bronchopulmonary aspergillosis in cystic fibrosis and HIV esophageal candidiasis are specialized infections that require targeted treatment approaches, often complicated by antibiotic resistance.
Addressing Hospital and Community-Acquired Infections
Hospital-acquired and community-acquired infections are increasingly difficult to treat due to the rising prevalence of resistant strains, emphasizing the need for new antibiotics.
Bioseutica®'s Commitment
Bioseutica® is at the forefront of this fight against antibiotic resistance. Our commitment is reflected in our robust research and development pipeline, focusing on novel polyene treatments for fungal antibiotic-resistant infections. Our dedicated team of scientists and healthcare professionals is working tirelessly to bring new, effective solutions to patients worldwide, aiming to turn the tide against this global health challenge. Bioseutica®'s AMCIPATRICIN operates similarly to other polyene antibiotics, primarily targeting and disrupting fungal cell membranes. Its effectiveness is attributed to the action of ergosterol-binding partricin agents, which cause the cell membrane to leak cytoplasmic material. This leakage disrupts the fungal cell's internal equilibrium, ultimately resulting in cell death. Due to its ability to destabilize the cell membranes of fungi, AMCIPATRICIN is highly effective against various fungal infections:
Potential Applications - Fungal Infection Treatments:
- Fungal Asthma Treatment
- Candidiasis – Invasive Candidiasis Treatment
- Aspergillosis – Invasive Aspergillosis Treatment
- Treatment for Allergic Bronchopulmonary Aspergillosis in Cystic Fibrosis
- HIV Esophageal Candidiasis Treatment
- Hospital Infections Treatment
- Community-Acquired Infections Treatment
